Skip to main content

Advertisement

Table 2 Treatment outcomes in afatinib and erlotinib arm

From: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

  Afatinib (%) Erlotinib (%) p-value
Best response    0.09
  CR 0 (0.0) 0 (0.0)  
  PR 5 (20.0) 2 (7.1)  
  SD 12 (48.0) 9 (32.1)  
  PD 8 (32.0) 17 (60.7)  
Objective response rate 5 (20.0) 2 (7.1) 0.17
Disease control rate 17 (68.0) 11 (39.3) 0.04
Objective response of brain metastases 3 (12.0) 4 (14.3) 0.81
Median duration of treatment (months, range) 4.5 (0.2–22.7) 3.3 (0.3–48.7) 0.52
Median time to progression (months, range) 3.3 (0.2–12.6) 3.3 (0.3–14.4) 0.77
Median PFS (95 % CI) (months) 4.1 (2.7–5.5) 3.3 (2.2–4.4) 0.97
Median OS (95 % CI) (months) 10.3 (7.5–13.0) 10.8 (7.4–14.2) 0.51
  1. Abbreviations: CI confidence interval, CR complete response, PD progressive disease, PFS progression-free survival, PR partial response, SD stable disease, TKI tyrosine-kinase inhibitor